A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults With Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment

Trial Profile

A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults With Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment

Completed
Phase of Trial: Phase III

Latest Information Update: 03 May 2017

At a glance

  • Drugs Ganaxolone (Primary)
  • Indications Partial epilepsies; Seizures
  • Focus Registrational; Therapeutic Use
  • Sponsors Marinus Pharmaceuticals
  • Most Recent Events

    • 28 Apr 2017 Results of post-hoc analysis presented at the 69th Annual Meeting of the American Academy of Neurology
    • 19 Jan 2017 This trial was discontinued in Bulgaria.
    • 03 Jan 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top